Glycogen storage disease type II (NORD)

97,505views

Glycogen storage disease type II (NORD)

Watch later

Watch later

Necrosis and apoptosis
Inheritance patterns
Cervical cancer
Innate immune system
B- and T-cell memory
B-cell development
MHC class I and MHC class II molecules
Inflammation
Cell-mediated immunity of natural killer and CD8 cells
T-cell development
Introduction to the immune system
Cell-mediated immunity of CD4 cells
Immunodeficiencies: Combined T-cell and B-cell disorders: Pathology review
Immunodeficiencies: T-cell and B-cell disorders: Pathology review
Development of the placenta
Development of twins
Development of the umbilical cord
Development of the fetal membranes
Mendelian genetics and punnett squares
Hardy-Weinberg equilibrium
Inheritance patterns
Independent assortment of genes and linkage
Evolution and natural selection
Down syndrome (Trisomy 21)
Edwards syndrome (Trisomy 18)
Patau syndrome (Trisomy 13)
Fragile X syndrome
Huntington disease
Myotonic dystrophy
Friedreich ataxia
Turner syndrome
Klinefelter syndrome
Prader-Willi syndrome
Angelman syndrome
Beckwith-Wiedemann syndrome
Cri du chat syndrome
Williams syndrome
Alagille syndrome (NORD)
Achondroplasia
Polycystic kidney disease
Familial adenomatous polyposis
Familial hypercholesterolemia
Hereditary spherocytosis
Li-Fraumeni syndrome
Marfan syndrome
Multiple endocrine neoplasia
Neurofibromatosis
Tuberous sclerosis
von Hippel-Lindau disease
Albinism
Cystic fibrosis
Gaucher disease (NORD)
Glycogen storage disease type I
Glycogen storage disease type II (NORD)
Glycogen storage disease type III
Glycogen storage disease type IV
Glycogen storage disease type V
Hemochromatosis
Mucopolysaccharide storage disease type 1 (Hurler syndrome) (NORD)
Krabbe disease
Leukodystrophy
Niemann-Pick disease types A and B (NORD)
Niemann-Pick disease type C
Primary ciliary dyskinesia
Phenylketonuria (NORD)
Sickle cell disease (NORD)
Tay-Sachs disease (NORD)
Alpha-thalassemia
Beta-thalassemia
Wilson disease
Alport syndrome
X-linked agammaglobulinemia
Fabry disease (NORD)
Glucose-6-phosphate dehydrogenase (G6PD) deficiency
Hemophilia
Mucopolysaccharide storage disease type 2 (Hunter syndrome) (NORD)
Lesch-Nyhan syndrome
Muscular dystrophy
Ornithine transcarbamylase deficiency
Wiskott-Aldrich syndrome
Mitochondrial myopathy
Autosomal trisomies: Pathology review
Muscular dystrophies and mitochondrial myopathies: Pathology review
Miscellaneous genetic disorders: Pathology review
Complement system
Liver anatomy and physiology
Cholestatic liver disease
Gallstones
Liver histology
Cirrhosis: Clinical
Non-alcoholic fatty liver disease
Anatomy of the pelvic girdle
Fascia, vessels and nerves of the upper limb
Anatomy of the brachial plexus
Cell cycle
Mitosis and meiosis
Metaplasia and dysplasia
Gel electrophoresis and genetic testing
DNA mutations
Heart failure

Transcript

Watch video only

Pompe disease, also called glycogen storage disease type II, is a genetically inherited condition caused by insufficient functioning of an enzyme called lysosomal acid alpha-1,4-glucosidase, or just acid alpha-glucosidase, and it’s caused by a mutation of the GAA gene. It’s named after the Dutch pathologist, Dr. J.C. Pompe, who first described it in 1932.

Glucose is used for energy by most cells of the body, and it’s stored inside the cells as a compact, branch-shaped molecule called glycogen. When a cell needs energy, it uses enzymes to remove glucose molecules from the branches. One of the organelles within the cell is the lysosome, which functions a bit like a tiny recycling plant. The lysosome contains enzymes that break down cellular substances so that they can be recycled. Now for some reason, and it’s not really understood why, but small amounts of glycogen end up in the lysosomes, where it’s broken down by an enzyme called acid alpha-glucosidase, to release glucose from the glycogen chain.

In Pompe disease, a mutation of the GAA gene prevents the production of enough functional acid alpha-glucosidase, and as a result, lysosomes can’t break down glycogen. This leads to a buildup of glycogen within the cytoplasm and lysosomes, and that leads to cellular damage and destruction.

Now, normally, glycogen is found in the largest amounts in the cytoplasm of liver cells and all three types of muscle cell. In individuals with Pompe, glycogen mostly accumulates in the lysosomes of those cells. Skeletal muscles include various muscles of the body as well as the diaphragm which is the primary breathing muscle. Cardiac muscle makes up the majority of the heart, and smooth muscle is found in the walls of blood vessels and many other organs.

Pompe disease is an autosomal recessive condition - so in other words, both parents must be carriers. The severity of the condition depends on how much functional acid alpha-glucosidase is produced. If little to no enzyme exists, the infantile-form of the condition typically occurs. Within the first few months of life, muscular damage to the heart develops, causing hypertrophic cardiomyopathy or an enlarged heart and eventual heart failure. Skeletal muscle weakness causes severely decreased muscle tone of the entire body. Weakness of the diaphragm and other breathing muscles lead to respiratory failure as well. Other findings include an enlarged liver which is thought to be largely due to heart failure, and a large tongue, which is primarily made of muscle.